Andrew P. Riley
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Andrew P. Riley has a total of 88 co-authors. Here are the top co-authors by number of shared publications:
- Richard M. van Rijn
Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette, Indiana 47907, United States
6 shared publications Lisa E. Rusali
Department of Pharmaceutical Sciences, College of Pharmacy
5 shared publications- Simone V. Bigi-Botterill
Exscientia, Boston, Massachusetts 02109, United States
5 shared publications - Carolyn J. Straub
Department of Pharmaceutical Sciences, College of Pharmacy, University of Illinois Chicago, Chicago, Illinois 60612, United States
4 shared publications Anna M. Gutridge
Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette, Indiana 47907, United States
3 shared publications- Craig William Lindsley
Vanderbilt University
3 shared publications
Latest Publications
- 18 October 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (21) , 24960-24974
Ligands Targeting α9-Containing Nicotinic Acetylcholine Receptors: Structure−Activity Relationships and Therapeutic Potential in Neuropathic Pain
Neuropathic pain remains a significant clinical challenge due to the varying efficacies and aversive effects associated with the currently available treatments. Most notably, the addiction potential associated with opioid use for pain presents a critical need for non-opioid-targeting analgesics. In the last two decades, α9-containing nicotinic acetylcholine receptors (nAChRs) have been evaluated preclinically for their potential as a new target for neuropathic pain therapies. In this perspective, we discuss several classes of ligands that modulate these receptors, highlighting hurdles that have arisen during their development and efforts that have been made to improve their therapeutic potential. Additionally, we consider the significant role these ligands have played in current and future drug discovery for this target.
- 18 October 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (21) , 24960-24974
Ligands Targeting α9-Containing Nicotinic Acetylcholine Receptors: Structure−Activity Relationships and Therapeutic Potential in Neuropathic Pain
Neuropathic pain remains a significant clinical challenge due to the varying efficacies and aversive effects associated with the currently available treatments. Most notably, the addiction potential associated with opioid use for pain presents a critical need for non-opioid-targeting analgesics. In the last two decades, α9-containing nicotinic acetylcholine receptors (nAChRs) have been evaluated preclinically for their potential as a new target for neuropathic pain therapies. In this perspective, we discuss several classes of ligands that modulate these receptors, highlighting hurdles that have arisen during their development and efforts that have been made to improve their therapeutic potential. Additionally, we consider the significant role these ligands have played in current and future drug discovery for this target.
- Open Access
- 28 April 2026
- Published by American Chemical Society (ACS) in Journal of Natural Products
- Vol. 89 (5) , 1597-1609
The Human Gut Microbiome Metabolizes Diverse Bioactive Coumarins via α,β-Unsaturated Lactone Reduction
The gut microbiome can influence drug efficacy through the direct metabolism of bioactive molecules. Despite numerous high-throughput screens for drug-microbiome interactions, the gut microbial metabolism of many bioactive compounds and its impact on treatment efficacy remain uncharacterized. We chose to investigate coumarins, which are a large class of bioactive natural products and chemical scaffolds for synthetic drugs. The core of the class, 1,2-benzopyrone, is metabolized by the microbiome to yield 3,4-dihydrocoumarin and melilotic acid via α,β-unsaturated lactone reduction. To explore the scope of this pathway, we screened a structurally diverse group of 12 bioactive coumarins using semitargeted LC-MS/MS metabolomics and ex vivo cultures of human feces. The culturable gut microbiome can reduce the α,β-unsaturated lactone of isocoumarin, simple, furano, pyrano, and prenylated coumarins with an unsubstituted 3,4-alkene bond. In a monoculture screen of microbiome isolates, we determined that 11 species could metabolize multiple coumarins through this pathway. Further, we demonstrate the direct coumarin-reducing capability of N-ethylmaleimide reductase from Escherichia coli. Finally, gut microbial metabolites of methoxsalen had diminished cytotoxicity against melanoma cancer cells compared to the parent drug. In summary, the human gut microbiome utilizes a single metabolic pathway to modulate the bioactivities of many coumarins.
- 28 April 2026
- Published by American Chemical Society (ACS) in Journal of Natural Products
- Vol. 89 (5) , 1597-1609
Open AccessThe Human Gut Microbiome Metabolizes Diverse Bioactive Coumarins via α,β-Unsaturated Lactone Reduction
The gut microbiome can influence drug efficacy through the direct metabolism of bioactive molecules. Despite numerous high-throughput screens for drug-microbiome interactions, the gut microbial metabolism of many bioactive compounds and its impact on treatment efficacy remain uncharacterized. We chose to investigate coumarins, which are a large class of bioactive natural products and chemical scaffolds for synthetic drugs. The core of the class, 1,2-benzopyrone, is metabolized by the microbiome to yield 3,4-dihydrocoumarin and melilotic acid via α,β-unsaturated lactone reduction. To explore the scope of this pathway, we screened a structurally diverse group of 12 bioactive coumarins using semitargeted LC-MS/MS metabolomics and ex vivo cultures of human feces. The culturable gut microbiome can reduce the α,β-unsaturated lactone of isocoumarin, simple, furano, pyrano, and prenylated coumarins with an unsubstituted 3,4-alkene bond. In a monoculture screen of microbiome isolates, we determined that 11 species could metabolize multiple coumarins through this pathway. Further, we demonstrate the direct coumarin-reducing capability of N-ethylmaleimide reductase from Escherichia coli. Finally, gut microbial metabolites of methoxsalen had diminished cytotoxicity against melanoma cancer cells compared to the parent drug. In summary, the human gut microbiome utilizes a single metabolic pathway to modulate the bioactivities of many coumarins.
- 17 December 2025
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 17 (1) , 1-19
Fifteen Years, One Mission: Innovative, Inspirational, and Impactful Discoveries
- 17 December 2025
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 17 (1) , 1-19
Fifteen Years, One Mission: Innovative, Inspirational, and Impactful Discoveries
- 19 November 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (22) , 23641-23642
Structural Biology Enabling Drug Discovery
- 19 November 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (22) , 23641-23642
Structural Biology Enabling Drug Discovery
- 11 September 2025
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 16 (9) , 1688-1689
In This Issue, Volume 16, Issue 9
- 11 September 2025
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 16 (9) , 1688-1689
In This Issue, Volume 16, Issue 9
- 14 August 2025
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 16 (8) , 1435-1436
In This Issue, Volume 16, Issue 8
- 14 August 2025
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 16 (8) , 1435-1436
In This Issue, Volume 16, Issue 8
- Open Access
- 30 July 2025
- Published by Royal Society of Chemistry (RSC) in Natural Product Reports
- Vol. 42 (10) , 1664-1675
Semi-synthesis in the exploration of opioid-targeting natural products
Chemically modifying a natural product can be a powerful tool for studying and optimizing its biological activity. This highlight presents recent examples of applying this approach to investigate natural products that target the opioid receptors.
- 30 July 2025
- Published by Royal Society of Chemistry (RSC) in Natural Product Reports
- Vol. 42 (10) , 1664-1675
Open AccessSemi-synthesis in the exploration of opioid-targeting natural products
Chemically modifying a natural product can be a powerful tool for studying and optimizing its biological activity. This highlight presents recent examples of applying this approach to investigate natural products that target the opioid receptors.
- 8 May 2025
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 16 (5) , 702-703
In This Issue, Volume 16, Issue 4
- 8 May 2025
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 16 (5) , 702-703
In This Issue, Volume 16, Issue 4
- 23 January 2025
- Published by Elsevier in Neuropharmacology
- Vol. 268, 110316
Pharmacological characterization of the novel selective kappa opioid receptor agonists 10-Iodo-Akuammicine and 10-Bromo-akuammicine in mice
- 23 January 2025
- Published by Elsevier in Neuropharmacology
- Vol. 268, 110316
Pharmacological characterization of the novel selective kappa opioid receptor agonists 10-Iodo-Akuammicine and 10-Bromo-akuammicine in mice
- 17 December 2024
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 16 (3) , 406-409
Derivatives of Aristoquinoline Accessed through a Ritter-like Reaction
The alkaloid aristoquinoline (1a) and its non-natural isomer isoaristoquinoline (1b) are inhibitors of the α3β4 nicotinic acetylcholine receptor (nAChR). A Ritter-like reaction was used to form the [3.3.1]- and [3.2.1]-azabicyclic scaffolds found in 1a and 1b, respectively. Although the electronic properties of the aryl nitrile did not influence product ratios or enhance the enantioselectivity of the reaction, changes to the aliphatic core led to the exclusive formation of [3.2.1]-azabicyclic products. Reduction of the imine products yielded a series of 1a and 1b derivatives that inhibit α3β4 nAChRs, including several derivatives with improved potency relative to those of 1a and 1b.
- 17 December 2024
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 16 (3) , 406-409
Derivatives of Aristoquinoline Accessed through a Ritter-like Reaction
The alkaloid aristoquinoline (1a) and its non-natural isomer isoaristoquinoline (1b) are inhibitors of the α3β4 nicotinic acetylcholine receptor (nAChR). A Ritter-like reaction was used to form the [3.3.1]- and [3.2.1]-azabicyclic scaffolds found in 1a and 1b, respectively. Although the electronic properties of the aryl nitrile did not influence product ratios or enhance the enantioselectivity of the reaction, changes to the aliphatic core led to the exclusive formation of [3.2.1]-azabicyclic products. Reduction of the imine products yielded a series of 1a and 1b derivatives that inhibit α3β4 nAChRs, including several derivatives with improved potency relative to those of 1a and 1b.